雙極性情感障礙市場：按類型、按藥物類別、按疾病類型、按給藥途徑、按分銷管道、按地區、機會、預測，2017-2031 年

全球雙極性情感障礙市場規模預計將從 2023 年的 50.1 億美元成長到 2031 年的 63.5 億美元，2024-2031 年的複合年增長率為 3.01%。雙相情感障礙市場的成長是由全球雙相情感障礙疾病負擔不斷增加、人們對心理健康意識的提高、早期有效診斷的診斷方法數量不斷增加、市場參與者提供的創新產品等推動的。因素

雙極性情感障礙是一種以極端情緒波動為特徵的精神疾病，包括躁狂和憂鬱發作。治療通常會結合藥物治療（例如情緒穩定劑或抗精神病藥物）和心理治療（例如認知行為治療（CBT））。個人化的方法至關重要，通常結合生活方式的改變和支持系統來幫助有效管理症狀。定期監測和調整治療計劃對於實現雙相情感障礙的穩定和改善生活品質至關重要。隨著越來越多的人關注心理健康，治療雙相情感障礙的藥物市場正在不斷增長。圍繞精神疾病的恥辱正在消除，更好的治療機會也正在出現。利用穿戴式裝置和人工智慧等數位工具的早期診斷進一步推動了市場成長。市場的主要課題是延長治療時間和患者用藥依從性。然而，由於市場進入者努力提供更好的替代品，市場成長持續上升。

本報告研究了全球雙相情感障礙市場，按類型、藥物類別、疾病類型、給藥途徑、分銷管道、地區以及參與市場的公司概況提供了市場概述。

目錄

第1章 專案範圍與定義

第2章 研究方法

第3章 執行摘要

第 4 章 2017-2031 年全球雙極性情感疾患市場展望

• 市場規模分析與預測
• 市佔率分析及預測
• 2023 年市場地圖分析
  • 按類型
  • 按藥物類別
  • 依故障類型
  • 按給藥途徑
  • 按分銷渠道
  • 按地區

第5章 2017-2031 年北美雙極性情感疾患市場展望

第6章 歐洲雙極性情感疾患市場展望，2017-2031

第7章 2017-2031 亞太地區雙極性情感疾患市場展望

第 8 章 2017-2031 南美洲雙極性情感疾患市場展望

第 9 章 2017-2031 年中東與非洲雙極性情感疾患市場展望

第10章供需分析

第11章 價值鏈分析

第12章 波特五力分析

第13章 PESTLE分析

第14章價格分析

第15章 市場動態

第16章市場趨勢與發展

第17章 監理框架與創新

第18章 專利情況

第19章案例研究

第20章 競爭格局

• 前5名市場領導者的競爭矩陣
• 前5名參與企業SWOT分析
• 前10名入市企業現狀
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Janssen Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Bristol Myers Squibb Company
  • Pfizer Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • AstraZeneca PLC

第21章 戰略建議

第22章 查詢及免責聲明

Global bipolar disorder market is projected to witness a CAGR of 3.01% during the forecast period 2024-2031, growing from USD 5.01 billion in 2023 to USD 6.35 billion in 2031. The growth in the bipolar disorder market is anticipated to be fueled by factors like the growing disease burden of bipolar disorder worldwide, growing concerns about mental health, increased diagnostics methods for early and effective diagnosis coupled with innovative product offerings from market players.

Bipolar disorder is a mental health condition characterized by extreme mood swings, including episodes of mania and depression. Treatment typically involves a combination of medications, such as mood stabilizers and antipsychotics, and psychotherapy, including cognitive behavioral therapy (CBT). A personalized approach is essential, often incorporating lifestyle changes and support systems to help manage symptoms effectively. Regular monitoring and adjustments to the treatment plan are crucial for achieving stability and improving the quality of life for individuals with bipolar disorders. The market for pharmaceutical treatment options for bipolar disorder is on the rise owing to increased emphasis on mental health and attention being given to mental wellness these days. The stigma associated with mental diseases is now clearing up, thus opening the door to opportunities for better treatment. Early diagnostic methods that utilize digital tools like wearable devices and artificial intelligence further drive the growth in the market. The major challenge in this market is the longer duration of treatment and patient adherence to it. However, the efforts of market players to provide better alternatives keep market growth on the rise. For instance, in April 2024, Vanda Pharmaceuticals Inc. received FDA approval for its atypical antipsychotic Fanapt (iloperidone) to treat manic or mixed episodes in adults with bipolar I disorder. Based on a Phase III clinical trial involving around 400 patients, this approval demonstrated significant improvements in mania severity compared to placebo. Fanapt, previously approved for schizophrenia, offers flexible dosing and a well-established safety profile.

Growing Bipolar Disease Burden to Boost Market Demand

The rising tide of bipolar disorder has a profound implication on the demand side of this market for therapeutics. Growing awareness and more developed diagnostic practices have increased the prevalence, so more patients find treatment. Extreme mood swings characterize bipolar disorder; hence the condition continues to create continuous demand for mood stabilizers, antipsychotics, and psychotherapy. Increased loss of productivity and healthcare costs attributable to the disorder have made governments and organizations concentrate more on initiatives that improve mental health, thus pushing the growth rate even higher in the market. Advances in research and development have also resulted in novel therapies that are effective and attractive to treatment. As acceptance within society of mental health issues improves, more patients are expected to seek help, increasing overall expansion in the bipolar therapeutics market. This mix sets the bipolar disorder market up to have a great future in the coming years. For instance, as per WHO data, more than 40 million patients have bipolar disorder across the globe, and according to the latest Global Burden of Disease (GBD) study, around 2.4% of the global population is affected by bipolar disorder.

Advancements in Diagnostic Tools Drive Market Growth

Advances in diagnostic tools are also a significant growth area in the bipolar disorder market as sophisticated mechanisms increase the precision of their identification and subsequent treatments. Recent developments include a relatively simple blood test, which can diagnose as much as 30% of cases of bipolar disorder-especially in conjunction with online psychiatric assessments. This advance clarifies differences between bipolar disorder and other closely related diagnoses, such as major depressive disorder, often over-diagnosed. With growing awareness and reduced stigma, more patients seek timely diagnoses, thus fueling the market demand. Technological advancement also helps better manage patients by including mood pattern monitoring applications in the patient's smartphone. Increased diagnosis leads to interventions at earlier stages, thus better interventions and, subsequently, more drugs and therapies for the disorder of bipolar. This trend is expected to continue with further research and tools. For instance, in April 2024, SYNLAB International GmbH marked World Bipolar Day 2024 by announcing the launch of a revolutionary test for diagnosing bipolar disorder in France. The myEDIT-B test is the first clinically validated test for differentiating between bipolar disorder and unipolar depression, using RNA editing changes in patients' blood.

Mood Stabilizers Segment to Dominate With Highest Market Share

Mood stabilizers are one of the most used medications for bipolar disorder. They are effective in the stabilization of mood swings and the prevention of both manic and depressive episodes, thus holding the major share in the bipolar disorder market. Among all the discovered mood stabilizers, lithium was the first in use to treat patients with mania. It had long been used in the treatment of mania. It was known for its efficacy in reducing the frequency as well as severity of manic episodes with protection against depression. Other drugs have also been effective, the best examples being valproate and lamotrigine, though these are most effective for certain types of bipolar. They stabilize the shifting patterns of mood as much as possible, helping a person stay balanced and permitting daily functioning to improve. Adding further strength to their position as the foundation in bipolar disorder treatment is their ability to improve quality of life and prevent recurrence. For instance, several mood stabilizer drugs approved by USFDA in recent times include Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Aripiprazole (Abilify), Lurasidone (Latuda), Asenapine (Saphris), Cariprazine (Vraylar), and Lumateperone (Caplyta).

Asia-Pacific Dominates the Bipolar Disorder Market

Asia-Pacific is anticipated to register a fast CAGR and, thus, exponential growth. Compared to the historical years, the diagnosis and recognition of mental health conditions are more prevalent in Asia-Pacific now, thereby increasing the demand for efficient treatment options significantly. In addition, with the effect of continuous urbanization and a change in lifestyle increasing stress factors, more people are now approaching health professionals for solutions to these mental health issues. Improved governmental initiatives and a boost in healthcare infrastructure are also increasing psychiatric services and medications. At the same time, the Asia-Pacific region is witnessing increasing investment from pharmaceutical companies that focus on the research and development of new therapies targeted at the peculiar needs of diverse populations. Mental health is slowly eroding its stigma, and more patients are encouraged to seek treatment. As such, these factors make the Asia-Pacific market for bipolar disorder treatment a rising area and an attractive investment opportunity for stakeholders in the healthcare industry. For instance, according to the National Mental Health Survey conducted in India, the prevalence of bipolar disorder in India is 0.5%, which comes out to be affecting more than 7 million people in India.

Future Market Scenario (2024-2031F)

The rise of digital therapeutics and online cognitive behavioral therapy (CBT) offers accessible, effective management tools for patients. These platforms can reduce depressive symptoms and improve overall well-being by providing real-time support and monitoring.

Devices that monitor sleep patterns and physical activity are proving effective in managing symptoms. Research indicates that regular tracking of these factors can stabilize mood, leading to more tailored treatment approaches.

Discoveries related to specific genes, like AKAP11, provide a deeper understanding of bipolar disorder's molecular mechanisms, paving the way for novel therapies that target these pathways.

Key Players Landscape and Outlook

The market for pharmaceuticals for bipolar disorder is being catered to by several players ranging from small startups to global pharmaceutical giants. Recent market activities include innovative product launches, acquisition deals, and regulatory approvals, which are anticipated to expand the market in the forecast period.

In March 2024, Bristol Myers Squibb (BMS) completed its acquisition of Karuna Therapeutics, broadening its neuroscience portfolio. This strategic move includes the integration of KarXT (xanomeline-trospium), an innovative antipsychotic with a unique mechanism of action, which is currently under review for treating schizophrenia. Notably, KarXT is also in trials for additional indications, including Bipolar I disorder, and agitation associated with Alzheimer's disease, highlighting its potential to address a range of mental health conditions. The acquisition is expected to bolster BMS's growth trajectory, aligning with its commitment to expanding treatment options in neuroscience.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Bipolar Disorder Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Generic
    • 4.2.1.2. Branded
  • 4.2.2. By Drug Class
    • 4.2.2.1. Mood Stabilizer
    • 4.2.2.2. Anticonvulsants
    • 4.2.2.3. Anti-Psychotic Drugs
    • 4.2.2.4. Anti-Depressant Drugs
    • 4.2.2.5. Anti-Anxiety Drugs
  • 4.2.3. By Disorder Type
    • 4.2.3.1. Bipolar I Disorder
    • 4.2.3.2. Bipolar II Disorder
    • 4.2.3.3. Cyclothymic Disorder
  • 4.2.4. By Route of Administration
    • 4.2.4.1. Oral
    • 4.2.4.2. Parenteral
  • 4.2.5. By Distribution Channel
    • 4.2.5.1. Hospital Pharmacies
    • 4.2.5.2. Retail Pharmacies
    • 4.2.5.3. Online Pharmacies
  • 4.2.6. By Region
    • 4.2.6.1. North America
    • 4.2.6.2. Europe
    • 4.2.6.3. Asia-Pacific
    • 4.2.6.4. South America
    • 4.2.6.5. Middle East and Africa
  • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Type
  • 4.3.2. By Drug Class
  • 4.3.3. By Disorder Type
  • 4.3.4. By Route of Administration
  • 4.3.5. By Distribution Channel
  • 4.3.6. By Region

5. North America Bipolar Disorder Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Type
    • 5.2.1.1. Generic
    • 5.2.1.2. Branded
  • 5.2.2. By Drug Class
    • 5.2.2.1. Mood Stabilizer
    • 5.2.2.2. Anticonvulsants
    • 5.2.2.3. Anti-Psychotic Drugs
    • 5.2.2.4. Anti-Depressant Drugs
    • 5.2.2.5. Anti-Anxiety Drugs
  • 5.2.3. By Disorder Type
    • 5.2.3.1. Bipolar I Disorder
    • 5.2.3.2. Bipolar II Disorder
    • 5.2.3.3. Cyclothymic Disorder
  • 5.2.4. By Route of Administration
    • 5.2.4.1. Oral
    • 5.2.4.2. Parenteral
  • 5.2.5. By Distribution Channel
    • 5.2.5.1. Hospital Pharmacies
    • 5.2.5.2. Retail Pharmacies
    • 5.2.5.3. Online Pharmacies
  • 5.2.6. By Country Share
    • 5.2.6.1. United States
    • 5.2.6.2. Canada
    • 5.2.6.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Bipolar Disorder Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Type
        • 5.3.1.2.1.1. Generic
        • 5.3.1.2.1.2. Branded
      • 5.3.1.2.2. By Drug Class
        • 5.3.1.2.2.1. Mood Stabilizer
        • 5.3.1.2.2.2. Anticonvulsants
        • 5.3.1.2.2.3. Anti-Psychotic Drugs
        • 5.3.1.2.2.4. Anti-Depressant Drugs
        • 5.3.1.2.2.5. Anti-Anxiety Drugs
      • 5.3.1.2.3. By Disorder Type
        • 5.3.1.2.3.1. Bipolar I Disorder
        • 5.3.1.2.3.2. Bipolar II Disorder
        • 5.3.1.2.3.3. Cyclothymic Disorder
      • 5.3.1.2.4. By Route of Administration
        • 5.3.1.2.4.1. Oral
        • 5.3.1.2.4.2. Parenteral
      • 5.3.1.2.5. By Distribution Channel
        • 5.3.1.2.5.1. Hospital Pharmacies
        • 5.3.1.2.5.2. Retail Pharmacies
        • 5.3.1.2.5.3. Online Pharmacies
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Bipolar Disorder Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Bipolar Disorder Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Bipolar Disorder Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Bipolar Disorder Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Clinical Trials
• 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. AbbVie Inc.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. GlaxoSmithKline plc
  • 20.3.3. Eli Lilly and Company
  • 20.3.4. Janssen Pharmaceuticals, Inc.
  • 20.3.5. Astellas Pharma Inc.
  • 20.3.6. Bristol Myers Squibb Company
  • 20.3.7. Pfizer Inc.
  • 20.3.8. Novartis AG
  • 20.3.9. Otsuka Pharmaceutical Co., Ltd.
  • 20.3.10. AstraZeneca PLC

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 3. Global Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 4. Global Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 5. Global Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 6. Global Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 7. Global Bipolar Disorder Market Share (%), By Region, 2017-2031F
• Figure 8. North America Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 9. North America Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 10. North America Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 11. North America Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 12. North America Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 13. North America Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 14. North America Bipolar Disorder Market Share (%), By Country, 2017-2031F
• Figure 15. United States Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 16. United States Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 17. United States Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 18. United States Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 19. United States Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 20. United States Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 21. Canada Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 22. Canada Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 23. Canada Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 24. Canada Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 25. Canada Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 26. Canada Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 27. Mexico Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 28. Mexico Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 29. Mexico Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 30. Mexico Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 31. Mexico Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 32. Mexico Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 33. Europe Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 34. Europe Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 35. Europe Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 36. Europe Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 37. Europe Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 38. Europe Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 39. Europe Bipolar Disorder Market Share (%), By Country, 2017-2031F
• Figure 40. Germany Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 41. Germany Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 42. Germany Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 43. Germany Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 44. Germany Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 45. Germany Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 46. France Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 47. France Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 48. France Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 49. France Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 50. France Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 51. France Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 52. Italy Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Italy Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 54. Italy Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 55. Italy Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 56. Italy Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 57. Italy Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 58. United Kingdom Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 59. United Kingdom Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 60. United Kingdom Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 61. United Kingdom Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 62. United Kingdom Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 63. United Kingdom Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 64. Russia Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 65. Russia Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 66. Russia Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 67. Russia Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 68. Russia Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 69. Russia Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 70. Netherlands Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 71. Netherlands Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 72. Netherlands Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 73. Netherlands Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 74. Netherlands Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 75. Netherlands Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 76. Spain Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 77. Spain Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 78. Spain Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 79. Spain Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 80. Spain Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 81. Spain Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 82. Turkey Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 83. Turkey Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 84. Turkey Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 85. Turkey Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 86. Turkey Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 87. Turkey Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 88. Poland Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 89. Poland Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 90. Poland Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 91. Poland Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 92. Poland Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 93. Poland Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 94. South America Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 95. South America Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 96. South America Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 97. South America Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 98. South America Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 99. South America Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 100. South America Bipolar Disorder Market Share (%), By Country, 2017-2031F
• Figure 101. Brazil Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 102. Brazil Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 103. Brazil Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 104. Brazil Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 105. Brazil Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 106. Brazil Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 107. Argentina Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 108. Argentina Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 109. Argentina Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 110. Argentina Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 111. Argentina Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 112. Argentina Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 113. Asia-Pacific Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 114. Asia-Pacific Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 115. Asia-Pacific Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 116. Asia-Pacific Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 117. Asia-Pacific Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 118. Asia-Pacific Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 119. Asia-Pacific Bipolar Disorder Market Share (%), By Country, 2017-2031F
• Figure 120. India Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 121. India Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 122. India Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 123. India Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 124. India Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 125. India Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 126. China Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 127. China Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 128. China Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 129. China Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 130. China Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 131. China Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 132. Japan Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 133. Japan Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 134. Japan Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 135. Japan Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 136. Japan Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 137. Japan Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 138. Australia Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 139. Australia Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 140. Australia Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 141. Australia Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 142. Australia Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 143. Australia Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 144. Vietnam Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 145. Vietnam Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 146. Vietnam Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 147. Vietnam Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 148. Vietnam Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 149. Vietnam Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 150. South Korea Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 151. South Korea Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 152. South Korea Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 153. South Korea Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 154. South Korea Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 155. South Korea Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 156. Indonesia Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 157. Indonesia Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 158. Indonesia Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 159. Indonesia Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 160. Indonesia Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 161. Indonesia Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 162. Philippines Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 163. Philippines Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 164. Philippines Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 165. Philippines Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 166. Philippines Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 167. Philippines Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 168. Middle East & Africa Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 169. Middle East & Africa Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 170. Middle East & Africa Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 171. Middle East & Africa Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 172. Middle East & Africa Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 173. Middle East & Africa Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 174. Middle East & Africa Bipolar Disorder Market Share (%), By Country, 2017-2031F
• Figure 175. Saudi Arabia Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 176. Saudi Arabia Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 177. Saudi Arabia Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 178. Saudi Arabia Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 179. Saudi Arabia Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 180. Saudi Arabia Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 181. UAE Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 182. UAE Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 183. UAE Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 184. UAE Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 185. UAE Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 186. UAE Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 187. South Africa Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
• Figure 188. South Africa Bipolar Disorder Market Share (%), By Type, 2017-2031F
• Figure 189. South Africa Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
• Figure 190. South Africa Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
• Figure 191. South Africa Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
• Figure 192. South Africa Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
• Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 194. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 195. By Disorder Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 196. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023